Business Context and Reporting Period
This Form 8-K was filed by Stellar Biotechnologies, Inc. on May 15, 2018, reporting events occurring on May 11, 2018. The registrant is a British Columbia, Canada corporation with principal executive offices in Port Hueneme, California. The filing details the pricing and completion of a best efforts registered public offering of units.
Key Financial Metrics and Transaction Details
- Offering Size: 2,075,472 units priced at $2.65 per unit.
- Gross Proceeds: Approximately $5.5 million.
- Net Proceeds: Approximately $4.68 million after deducting fees and expenses.
- Placement Agent Fees: 7.0% cash placement fee, 1.0% management fee, $35,000 expense allowance, and up to $100,000 legal fee reimbursement.
- Placement Agent Warrants: 145,283 warrants issued to H.C. Wainwright & Co., LLC with an exercise price of $3.31 (125% of offering price).
- Investor Warrants: One warrant per unit, exercisable immediately at $2.65, expiring five years from issuance.
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement with investors and engaged H.C. Wainwright & Co., LLC as the exclusive placement agent. Each unit consists of one common share (or equivalent) and one warrant. The offering was completed on May 15, 2018. The filing does not provide comparative financial data (revenue, profit, or cash flow) as this is a current report regarding a capital raise rather than a periodic financial statement.
Outlook, Use of Proceeds, and Risks
Use of Proceeds: The Company intends to use net proceeds for general corporate purposes, including working capital, capital expenditures, and research and development expenses.
Warrant Restrictions: Holders cannot exercise warrants if the exercise would result in beneficial ownership exceeding 4.99% or 9.99% of outstanding common shares.
Lock-up: Placement Agent Warrants are subject to a six-month lock-up period under FINRA Rule 5110(g).
Investor Verification Checklist
- Verify the final number of units sold and actual gross proceeds in the press release dated May 15, 2018 (Exhibit 99.2).
- Confirm the exact amount of legal fees and other expenses deducted to calculate the final net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and warranties.
- Check subsequent filings for the actual exercise of warrants and any dilution impact on existing shareholders.